Menu

Reports

picture 89

The role of generic drugs in the EU

Home/Reports | Posted 12/08/2011

Today, generic medicines play an essential role in treating disease by increasing the accessibility and affordability of modern day pharmaceuticals.

picture 97

Diversification of Big Pharma into generics and biosimilars

Home/Reports | Posted 05/08/2011

The infamous patent cliff is upon us and most top multinational companies are highly exposed with thin pipelines [1]. In this current climate, companies can choose to play or defend to optimise their position against generics.

picture 91

Registration procedures for generic drugs in the EU

Home/Reports | Posted 05/08/2011

In the EU there are several different routes to marketing authorisation for generic drugs.

Centralised Procedure

Marketing authorisation is issued by the EMA and is valid for the entire EU/European Economic Area.

This procedure is optional for generics:

  • if the reference product is authorised via a centralised procedure (CP)
  • if a CP is in the interests of patients at a EU level.
picture 81

Quality control for generic drugs

Home/Reports | Posted 29/07/2011

GMP

Generic medicines manufacturers must comply with the strict rules of good manufacturing practice (GMP). This ensures that all medicines—generic and originator alike—are produced consistently and controlled to stringent standards of quality in accordance with current legislation.

picture58

Generic drugs – registration, quality, value and sustainability

Home/Reports | Posted 08/07/2011

In the current climate of economic downturn and with the impending ‘patent cliff’ threatening many major pharmaceutical companies, generic medicines are increasingly looking like a good option.

picture 65

Generic applications in the EU, patents and exclusivity

Home/Reports | Posted 01/07/2011

Types of protection on the originator molecule that have to be taken into account by generic drug manufacturers when filing applications for generic drugs in the EU include the following:

  • patents at the time of marketing
  • supplementary protection certificates at the time of marketing
  • data/regulatory exclusivity at the time of regulatory submission
  • market exclusivity at the time of marketing.
picture 61

Big Pharma and the generics industry

Home/Reports | Posted 24/06/2011

What with growth in the global pharmaceutical market slowing and even stabilising and the impending ‘patent cliff’ looming, Big Pharma needs to look for other options.

picture 84

Impact of healthcare reforms

Home/Reports | Posted 29/07/2011

Even though global pharmaceutical market growth has stabilised, it still means a rising medicines bill. The global pharmaceutical market is expected to add nearly US$300 billion through 2014, topping US$1.1 trillion [1].

picture 76

The growth in the generics industry

Home/Reports | Posted 08/07/2011

During 2010 there was unprecedented activity in the pricing and market access landscape, much of which has aided the growth in the generics industry during 2010. This activity occurred across three broad themes:

Patent cliff and the generics industry

Home/Reports | Posted 01/07/2011

An estimated US$186 billion in sales revenues of patent-protected medicines is likely to be exposed to generic competition between now and 2016 [1].